New company delivers AI-powered portfolio modeling platform to support capital allocation, risk management and innovation in drug development
Cambridge, MA–May 29, 2025–QLS Technologies LLC launched today as a spinout from QLS Advisors LLC, with a mission to apply financial engineering to foster innovation in the life sciences. As biomedicine has grown more complex, financing strategy has become a critical factor in enabling breakthrough therapies to achieve their maximum impact—extending longevity and improving quality of life for patients.
QLS Technologies has built a SaaS-based analytics and portfolio management platform, QLS Vantage, that employs a suite of AI-powered modeling tools to enable rapid valuation and scenario planning. The platform enables flexible plug-and-play deal modeling, robust asset forecasting, and AI-powered scenario optimization to systematically derisk drug development using the latest ML techniques and a wide array of public and proprietary data.
QLS Technologies brings together an interdisciplinary team of data scientist, biopharma operators, and finance experts who can deliver a wide range of services to our clients. Andrew Lo, QLS Technologies Co-Founder and Professor of Finance at the MIT Sloan School of Management commented: “Better risk management tools for biopharma professionals means more efficient use of capital, and more accurate estimates of risk and reward for investors. The Vantage platform is especially useful for navigating through biotech’s current capital-constrained environment.”
For product inquiries, please reach out to contact@qlstechnologies.com